As Covid pro­gram ad­vances, Enan­ta's new CMO says it's not 'lim­it­ed to an­tivi­ral­s'; With all eyes on Gilead-part­nered can­cer drugs, Ar­cus brings med­ical chief on board

Ex­pect some pipeline ad­just­ments at Enan­ta Phar­ma­ceu­ti­cals in the com­ing years, be­cause new CMO Scott Rot­ting­haus thinks the an­tivi­ral biotech can …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.